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Gastroesophageal reflux induced cough is a common cause of chronic cough, and proton pump inhibitors are a
standard therapy. However, the patients unresponsive to the standard therapy are difficult to treat and remain a
challenge to doctors. Here, we summarized the experience of successful resolution of refractory chronic cough due
to gastroesophageal reflux with baclofen in three patients. It is concluded that baclofen may be a viable option for
gastroesophageal reflux induced cough unresponsive to proton pump inhibitor therapy.
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Gastroesophageal reflux induced cough (GERC) is a
common cause of chronic cough and accounts for 5-
41% of chronic cough. [1] Although proton pump inhibi-
tors are a standard therapy for GERC, some patients do
not respond to the antireflux medical treatment and re-
main a challenge to doctors. Here, we report three
patients with GERC resistant to proton pump inhibitors
but successfully treated with baclofen.Case presentations
Patient 1
A 26-year-old male patient with persistent cough for 3.5
years was referred to our respiratory clinic. He com-
plained of cough day and night, with small amounts of
viscous sputum. The accompanying symptoms included
frequent clearing of the throat, occasional heartburn and
acid regurgitation, but no post-nasal drip and chest pain
(Table 1). The patient acknowledged a medical history of
allergic rhinitis for 7 years, denied any exposure to envir-
onmental or occupational irritants, and never smoked.
One year prior to the visit, he received a full diagnostic
work-up in another respiratory clinic, where the results
of laboratory investigations showed the normal chest* Correspondence: qiuzhongmin@yahoo.com.hk
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reproduction in any medium, provided the orradiographs and lung function, negative bronchial
provocation to methacholine, positive IgE specific to
dust mite and soybean in the serum, 1.5% of eosinophils
in induced sputum, normal findings in fiberobroncho-
scope, and only submucosal edema with infiltration of
scattered eosinophils and lymphocytes into airway mu-
cosa as described by the pathologist examining the bi-
opsy examples. A further 24-hour esophageal pH
monitoring revealed an abnormal acid-reflux with a
DeMeester score of 61.4 and the symptom association
probability of 99%. Then, the presumptive diagnosis of
GERC was established and oral omeprazole 20 mg twice
a day was commenced. Three months later, his heart-
burn and acid regurgitation disappeared while the cough
did not improve. The patient’s cough persisted despite
the subsequent treatment with oral montelukast and
inhaled corticosteroid.
Physical examination showed no other abnormal find-
ings except for erythema and “cobblestone” appearance
on the posterior pharyngeal mucosa. The repeated lung
function testing and bronchial challenge with histamine
were normal. Cytology in the induced sputum showed
41.5% of monocytes, 56.5% of lymphocytes and 2.0% of
eosinophils. The patient received a 2 week course of oral
chlorpheniramine, 4 mg three times a day for a possible
upper airway cough syndrome and then one week of oral
prednisone 25 mg daily for suspected eosinophilicThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical characteristics of the patients
Patient 1 Patient 2 Patient 3
Ages (yr) 26 63 42
Gender (M/F) M F M
Cough duration (month) 42 24 25
Heartburn Yes Yes No
Regurgitation Yes Yes Yes
Cough symptom score
Daytime 3 4 3
Nighttime 1 2 2
Cough threshold to capsaicin
C2(μmol/L) 0.49 0.49 1.95
C5(μmol/L) 31.2 1.95 7.8
FEV1 (%predicted) 99.1 101.8 86.1
FVC (%predicted) 96.9 104.0 96.1
FEV1/FVC (%) 89.5 83.8 75.0
PD20FEV1(μmol) >7.8 >7.8 >7.8
FEV1: forced expiratory volume in one second; FVC: forced vital capacity;
PD20FEV1: the cumulative provocative dose of histamine causing a 20% fall in
FEV1.
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channel intraluminal impedance combined with pH
monitoring (MII-pH) was ordered, and the abnormal
non-acid reflux and positive symptom association prob-
ability for non-acid reflux was found (Table 2). After 8
weeks of additional augmented antireflux medical ther-
apy comprising omeprazole, 20 mg twice a day and
domperidone, 10 mg three times a day, the patient did
not feel any improvement. Then, baclofen, 20 mg three
times a day was used to replace domperidone. The
patient's coughing decreased noticeably in a week, andTable 2 The results of multi-channel intraluminal
impedance combined with pH monitoring in the patients
Patient 1 Patient 2 Patient 3 Reference
value
DeMeester score 0.70 168.13 20.22 <14.72
SAP for acid reflux (%) 0.0 97.3 84.4 <95
SAP for nonacid reflux (%) 95.2 0.0 0.0 <95
Acidic reflux (n) 22.8 41.6 36.3 10-35
Weakly acidic reflux (n) 29.0 8.1 8.0 5-18
Weakly alkaline reflux (n) 23.4 2.3 1.1 1-7
Gas reflux (n) 26.2 13.9 11.4 3-17
Liquid reflux (n) 11.0 25.4 8.0 10-32
Mixed reflux (n) 64.6 26.6 37.5 11-26
Proximal extent (n) 3.0 5.2 4.3 4-17
Bolus exposure (%) 1.0 2.3 2.1 0.4-1.2
Bolus clearance (s) 10.0 9.0 14.5 8-13
SAP: symptom association probability.completely resolved in two months, as indicated by the
decreased cough symptom score and cough reflex sensi-
tivity to capsaicin (Figure 1). Within the next four
months of follow-up, no reoccurrence of cough was
reported. The dosage of baclofen has been reduced to 20
mg daily. No discernable side effects were noted during
the treatment with baclofen.
Patient 2
A 63-year-old housewife with a 2-year history of dry
cough was referred for the suspicious GERC. She
described that cough occurred through day and night,
and disturbed her sleep, with the occasional heartburn,
regurgitation and urinary incontinence (Table 1). The
triggers included the cold and smoky air. A past medical
history of hypertension and diabetes was present, but
angiotensin-converting enzyme inhibitors were not cur-
rently being taken. On physical examination, only the
follicular hyperplasia was found on the posterior
pharyngeal mucosa. Her chest radiographs and lung
function testing were normal, bronchial provocation
with histamine did not demonstrate the existence of air-
way hyperresponsiveness. Cell differentials in the
induced sputum consisted of 60.5% of monocytes, 37.0%
of lymphocytes, 2.0% of neutrophils and 0.5% of eosino-
phils. MII-pH showed a serious abnormal acid reflux
and positive symptom association probability for acid re-
flux (Table 2). When waiting for the results of the la-
boratory investigations, the patients was treated with
antihistamine/ decongestant for a week, but without
success.
No improvement in her cough and gastrointestinal
symptoms was noted with 8 weeks course of initial anti-
reflux medical treatment comprising omeprazole and
domperidone. Baclofen, 20 mg three times a day, was
given to substitute for domperidone. The patient`s
cough attenuated significantly in two weeks, and
resolved in three months, in companion with the im-
provement of cough symptom score and cough reflex
sensitivity to capsaicin (Figure 2). At 4-month review
after the initiation of baclofen, the patient only com-
plained of the occasional mild cough. The dizziness was
reported in the beginning of the treatment with baclo-
fen, but it was tolerable and waned in the two weeks.
Patient 3
A 42 year-old man with a 2-year history of persistent dry
cough was referred for the diagnosis of cause. He
coughed all the day, severely at postprandial time or
when going to bed. An occasional regurgitation was
described but without heartburn or the sensation of
postnasal drip (Table 1). The patient was a lifetime non-
smoker, and had no history of chronic rhinitis or occu-












































Figure 1 Changes in cough symptom score against the duration of the treatment with baclofen, and cough threshold C2 and C5 to
capsaicin when cough was resolved in Patient 1.
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and lung function examinations were within the normal
limits, and bronchial challenge confirmed airway hyper-
responsiveness, as shown by 3.0 μmol of the cumulative
provocative dose of histamine causing a 20% fall in
FEV1. Then, the diagnosis of cough variant asthma was
considered. However, the anti-asthma therapy including
the initial inhalation of salmeterol/fluticasone 50/250μg,
twice a day for one month and the subsequent trials
with oral prednisone and montelukast failed to relieve
the cough.
Physical examination was normal. The repeated bron-
chial provocation with histamine demonstrated the re-
covery of airway responsiveness. Cell examination in the
induced sputum showed 82.5% of macrophages,12.0% of
lymphocytes and 5.5% of neutrophils. MII-pH study was
performed which revealed a slight abnormal acid reflux































Figure 2 Changes in cough symptom score against the duration of th
capsaicin when cough was resolved in Patient 2.The initial trial with omeprazole plus domperidone
was unsuccessful. Thus, baclofen was added to the ther-
apy while domperidone was withdrawn. Cough signifi-
cantly improved within the 4 weeks and completely
resolved within the two months. The effectiveness was
also verified by the decreases in cough symptom score
and cough reflex sensitivity to capsaicin (Figure 3). The
dosage of baclofen was maintained for two months after
the resolution of cough, and then began to reduce in a
speed of 10mg a week. Since cough did not relapse with
the minimum dose of 20 mg daily, baclofen was stopped
two months later. No obvious adverse effect except for a
slight sleepiness was reported during the treatment with
baclofen.
Discussion
In the patients with presumptive GERC whose cough per-
sists despite proton pump inhibitors therapy, three possi-
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having continuing acid reflux that causes cough by micro-
aspiration or esophageal-tracheobronchial reflex [1]. 2.
non-acid (weakly acidic or alkaline) reflux is producing
cough. It is proposed that cough due to non-acid reflux is
resistant to proton pump inhibitors since they only reduce
the pH of the refluxate but not the amount and the rate of
reflux episodes [2]. 3. the ongoing cough is not related to
any continuing reflux. It has been reported that only
40.8% of the patients with the positive findings of 24 hour
esophageal pH monitoring were responsive to the high
dose of omeprazole [3]. In all the three patients, MII-pH
uncovered the abnormal acid or nonacid reflux and the
temporal association between reflux and cough. There-
fore, GERC could be established since the other common
causes of chronic cough such as upper airway cough syn-
drome, cough variant asthma and eosinophilic bronchitis
were excluded with the previous investigation procedure
and specific therapies. The diagnosis of GERC was finally
confirmed by the favorable response to the subsequent
antireflux treatment containing omeprazole and baclofen
even though the initial standard antiacid medical treat-
ment failed.
In theory, the therapeutic options available for refrac-
tory GERC resistant to proton pump inhibitors include
prokinetic agents, transient lower esophageal sphincter
relaxation inhibitors and antireflux surgery because they
all have the ability to reduce the frequency of reflux and
volume of refluxate. At present, the efficacy of prokinetic
agents has not been ascertained, which can explain the
failure of the initial antireflux therapy containing dom-
peridone. Antireflux surgery should not be the preferred
choice when a cause and effect relationship between re-
flux and chronic cough is not definitely established. We
selected baclofen, a potent inhibitor of transient lower
esophageal sphincter relaxation, as an add-on trial for


































Figure 3 Changes in cough symptom score against the duration of th
capsaicin when cough was resolved in Patient 3.has been proposed in the management of difficult to
treat gastroesophageal reflux disesase [4]. To our know-
ledge, this is the first report for the successful resolution
of refractory GERC with baclofen.
Baclofen modulates the transient lower esophageal
sphincter relaxations mediated by vagal reflex pathways
through the activation of gamma-aminobutyric acid B
receptor. Considering transient lower esophageal sphinc-
ter relaxations account for the vast majority of reflux
events [5], it is predictable that baclofen may be helpful
for refractory GERC by the inhibition of both acid and
nonacid reflux. The limited studies have shown that it
decreased the frequency of transient lower esophageal
sphincter relaxations by 40-60% and acid or non-acid re-
flux episodes by 43% [6-8]. Vela has illustrated that
baclofen reduced the symptoms related to acid reflux by
72% and related non-acid reflux by 21% in a small co-
hort of patients with heartburn [9]. In addition, baclofen
has also been recognized for a long time to have a non-
specific antitussive activity both in animals [10] and in
humans [11,12]. There have been several lines of evi-
dence illustrating baclofen can treat the cough caused by
angiotensin-converting enzyme inhibitors [13] and re-
fractory chronic cough with unknown cause [14]. Our
observations revealed that 2–4 week course of baclofen
was needed for the significant alleviation of cough, and
the complete resolution was generally achieved in the
2–3 months. Because MII-pH is an invasive procedure,
our patients refused to undergo a repeated examination
after the cough was resolved. Therefore, we were unable
to directly evaluate the inhibitory efficacy of baclofen on
acid or non-acid reflux in the patients. Nevertheless, it
can be speculated that baclofen may play a therapeutic
role through the effective blockade of all types of reflux
events as well as the nonspecific antitussive effect.
A variety of central nervous system-related side effects
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adverse reactions consist of dry mouth, nausea, vomit-
ing, diarrhea or constipation. These side effects usually
occur in the early or high-dose phase of treatment, and
often limit the utility of baclofen in clinical practice [4].
In our patients, there was only slight dizziness and
sleepiness in patient 2 and 3 respectively, which did not
interrupt the treatment of baclofen. The lack of obvious
side effects may be attributed to the well tolerance of
the patients to the drug.
In conclusion, baclofen may be a viable option for re-
fractory cough due to gastroesophageal reflux. Further
study is needed to validate its therapeutic efficacy for
GERC in the future.
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